Literature DB >> 2720306

Antagonism of Paf-induced oedema formation in rabbit skin: a comparison of different antagonists.

P G Hellewell1, T J Williams.   

Abstract

1. Eight platelet activating factor (Paf) antagonists were evaluated as inhibitors of oedema formation in rabbit skin induced by intradermal injection of Paf plus prostaglandin E2 (PGE2). Antagonists were tested by both intradermal (i.d.) and intravenous (i.v.) routes. 2. Intradermal injection of two antagonists structurally-related to Paf (SRI 63-675 and CV-3988) resulted in a partial inhibition of Paf-induced oedema formation but at high doses of antagonist, marked agonist activities were detected. CV-3988 administered i.v. inhibited Paf-induced plasma leakage by 73-80%; however, oedema responses to a range of other inflammatory mediators were also reduced, albeit to a lesser extent (40-60%). SRI 63-675 administered i.v. did not significantly inhibit Paf-induced oedema. 3. The antagonist 48740 RP administered either i.d. or i.v. showed partial, but selective, inhibition of Paf-induced oedema formation, although the doses required were high when compared with other antagonists. 4. BN 52021 was a weak Paf antagonist when injected i.d., but following i.v. administration the responses to Paf were inhibited by 63-71%. Responses to all other mediators tested were unaffected. 5. Kadsurenone and its synthetic derivatives, L-652,731 and L-659,989 all blocked responses to Paf in the skin. L-659,989 was the most potent, achieving almost total inhibition when injected i.d. and i.v.; moreover, it was selective for Paf. L-652,731 was more potent than kadsurenone. 6. WEB 2086 given i.d. and i.v. showed similar activity to L-659,989 and it was also selective for Paf-induced oedema formation. 7. These results illustrate that in rabbit skin not all Paf antagonists are selective for Paf, some showing agonist-like activity which can mask antagonist properties. It is suggested that before ascribing a role for endogenous Paf in an inflammatory reaction based on results with antagonists, the activity of the antagonists in the model under investigation should be rigorously established.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720306      PMCID: PMC1854485          DOI: 10.1111/j.1476-5381.1989.tb11939.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021.

Authors:  P Braquet; A Etienne; C Touvay; R H Bourgain; J Lefort; B B Vargaftig
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

2.  Control of vascular permeability by polymorphonuclear leukocytes in inflammation.

Authors:  C V Wedmore; T J Williams
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

3.  Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.

Authors:  T Y Shen; S B Hwang; M N Chang; T W Doebber; M H Lam; M S Wu; X Wang; G Q Han; R Z Li
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

4.  Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin.

Authors:  J Morley; C P Page; W Paul
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

5.  Synergism between platelet-activating factor (PAF-acether) and prostaglandin E2 in man.

Authors:  D V McGivern; G S Basran
Journal:  Eur J Pharmacol       Date:  1984-06-15       Impact factor: 4.432

6.  Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988.

Authors:  A C Issekutz; M Szpejda
Journal:  Lab Invest       Date:  1986-03       Impact factor: 5.662

7.  Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man.

Authors:  T W Evans; G Dent; D F Rogers; B Aursudkij; K F Chung; P J Barnes
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

8.  CV-3988 - a specific antagonist of platelet activating factor (PAF).

Authors:  Z Terashita; S Tsushima; Y Yoshioka; H Nomura; Y Inada; K Nishikawa
Journal:  Life Sci       Date:  1983-04-25       Impact factor: 5.037

9.  A specific antagonist of platelet-activating factor suppresses oedema formation in an Arthus reaction but not oedema induced by leukocyte chemoattractants in rabbit skin.

Authors:  P G Hellewell; T J Williams
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

10.  Detection of the complement fragment C5a in inflammatory exudates from the rabbit peritoneal cavity using radioimmunoassay.

Authors:  P J Jose; M J Forrest; T J Williams
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  10 in total

1.  Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor.

Authors:  D F Rogers; S Dijk; P J Barnes
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

Review 2.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

3.  Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505.

Authors:  F Pons; A G Rossi; K E Norman; T J Williams; S Nourshargh
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

4.  Involvement of platelet-activating factor in ultraviolet B-induced hyperalgesia.

Authors:  Qiwei Zhang; Leslie A Sitzman; Mohammad Al-Hassani; Shanbao Cai; Karen E Pollok; Jeffrey B Travers; Cynthia M Hingtgen
Journal:  J Invest Dermatol       Date:  2008-06-26       Impact factor: 8.551

5.  Inflammatory mechanisms in the passive cutaneous anaphylactic reaction in the rabbit: evidence that novel mediators are involved.

Authors:  P G Hellewell; P J Jose; T J Williams
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

6.  Platelet activating factor and systemic anaphylaxis in Nippostrongylus brasiliensis-sensitized rats: differential effects of PAF antagonists.

Authors:  R Mathison; J S Davison; A D Befus
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

7.  Characteristics of oedema formation induced by N-formyl-methionyl-leucyl-phenylalanine in rabbit skin.

Authors:  P G Hellewell; H Yarwood; T J Williams
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

8.  The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit.

Authors:  G R May; W Paul; P Crook; K D Butler; C P Page
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

9.  Actin assembly in electropermeabilized neutrophils: role of intracellular calcium.

Authors:  G P Downey; C K Chan; S Trudel; S Grinstein
Journal:  J Cell Biol       Date:  1990-06       Impact factor: 10.539

Review 10.  New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.

Authors:  Jeffrey B Travers; Joyce G Rohan; Ravi P Sahu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-15       Impact factor: 6.055

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.